Dr. Gong on Adverse Events of TKI VEGF-Directed Therapy in RCC

Video

Jun Gong, MD, fellow, City of Hope, discusses adverse events (AEs) associated with TKI/VEGF-directed therapy for patients with metastatic renal cell carcinoma (RCC).

Jun Gong, MD, fellow, City of Hope, discusses adverse events (AEs) associated with TKI/VEGF-directed therapy for patients with metastatic renal cell carcinoma (RCC).

In a study evaluating latency of potential treatment-related AEs, toxicities reported after the first drug claim up until the last drug claim were tracked. With a population of a little over 1000 and a median age of 62, the most common AEs were fatigue, hypertension, diarrhea and thyroid dysfunction. The median time of onset reported by patients was beyond 100 days.

Some side effects are more easily reportable, such as nausea or vomiting, but something that is determined by a blood test might not show symptoms. The number of patients who don’t report symptoms or decide to wait them out was much higher than researchers anticipated.

The next steps, says Gong, is telling the scientific community that there needs to be more investigation into side effects, as many phase II and III RCC studies do not report time of onset toxicities.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
© 2025 MJH Life Sciences

All rights reserved.